North American Report

Adrenal Cortex Neoplasms Market: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight

 Breaking News
  • No posts were found

Adrenal Cortex Neoplasms Market: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight

October 10
15:28 2021
Adrenal Cortex Neoplasms Market: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight
Adrenal Cortex Neoplasms Market

DelveInsight’s Adrenal Cortex Neoplasms Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Adrenal Cortex Neoplasms, historical and forecasted epidemiology as well as the Adrenal Cortex Neoplasms market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Adrenal Cortex Neoplasmsis rare cancer that originates in the outer layer of the adrenal gland. ACC is also called cancer of the adrenal cortex. A tumor of the adrenal cortex may be functioning (produces surplus hormones than usual) or nonfunctioning (does not produce surplus hormones than usual). Most adrenocortical tumors are functioning.

 

Some facts of Adrenal Cortex Neoplasms Market are:

  • Adrenal Cortex Neoplasms is a rare malignancy with poor prognosis. It occurs at any age, with two peak incidence: the first in the first decade and the second between 40‒50 years.
  • In the retrospective review conducted by Wang et al. titled “Prognostic Factors of Adrenal Cortex Neoplasms: An Analysis of the Surveillance Epidemiology and End Results (SEER) Database,” the study population of Adrenal Cortex Neoplasms consist of 60.6% females and 39.4% males. Most of the patients were in stage II (44.6%) followed by stage IV (28.1%), and stage III (21.8%). Only 5.5% of patients were found to be in stage I of the Adrenal Cortex Neoplasms.
  • According to the retrospective review conducted by Aspinall et al. titled “How is Adrenocortical Cancer being Managed in the UK?,” the incidence of Adrenal Cortex Neoplasms is 0.5‒2 per million per year.
  • According to the study by Johanssen et al. titled “Deficits in the Management of Patients With Adrenocortical Carcinoma in Germany,” the incidence of Adrenal Cortex Neoplasms is one per million population, and females are more frequently affected than males, with a female:male ratio of 1.5 : 1.
  • The United States has a high percentage of incident patients in 2017.
  • The emerging therapies for the treatment of Adrenal Cortex Neoplasms include Cabozantinib, EO2401, and others. The current research on the combination cytotoxic drugs will lead to the more emerging therapies.

 

Request for Sample Report: https://www.delveinsight.com/sample-request/adrenal-cortex-neoplasms-market

 

Scope of Adrenal Cortex Neoplasms Market are:

  • The Adrenal Cortex Neoplasms report covers the descriptive overview of Adrenal Cortex Neoplasms, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Adrenal Cortex Neoplasms epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Adrenal Cortex Neoplasms are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Adrenal Cortex Neoplasms market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Adrenal Cortex Neoplasms market

 

 

Some of Adrenal Cortex Neoplasms Companies are:

  • Pfizer
  • Millendo Therapeutics
  • Enterome
  • Novartis
  • Exelixis
  • Corcept Therapeutics
  • Astellas Pharma
  • And Many More

 

Some of Adrenal Cortex Neoplasms Therapies are:

  • Axitinib
  • ATR-101
  • EO2401
  • Relacorilant
  • Cabozantinib
  • Pembrolizumab
  • OSI-906

 

Request for Sample Report: https://www.delveinsight.com/sample-request/adrenal-cortex-neoplasms-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Adrenal Cortex Neoplasms

3. Competitive Intelligence Analysis for Adrenal Cortex Neoplasms

4. Adrenal Cortex Neoplasms: Market Overview at a Glance

4.1. Adrenal Cortex Neoplasms Total Market Share (%) Distribution in 2018

4.2. Adrenal Cortex Neoplasms Total Market Share (%) Distribution in 2030

5. Adrenal Cortex Neoplasms: Disease Background and Overview

6. Patient Journey

7. Adrenal Cortex Neoplasms Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Adrenal Cortex Neoplasms Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Adrenal Cortex Neoplasms: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Adrenal Cortex Neoplasms

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/adrenal-cortex-neoplasms-market